Skip to content
VuFind
Advanced
  • Bevacizumab in combination wit...
  • Cite this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
QR Code

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Bibliographic Details
Main Authors: Chan, Arlene, Miles, D., Pivot, X.
Format: Journal Article
Published: Oxford University Press 2010
Online Access:http://hdl.handle.net/20.500.11937/7623
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://hdl.handle.net/20.500.11937/7623

Similar Items

  • Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    by: Miles, D., et al.
    Published: (2013)
  • AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
    by: Gianni, L., et al.
    Published: (2013)
  • Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    by: Miles, D., et al.
    Published: (2010)
  • HER2 positive metastatic breast cancer: What happens after first line failure?
    by: Chan, Arlene
    Published: (2016)
  • Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
    by: Cinieri, S., et al.
    Published: (2017)

Search Options

  • Advanced Search

Find More

  • Browse the Catalog

Need Help?

  • Search Tips